News | May 8, 2026
A recent study by Tatyana Avilova, Economist at Secretariat has been selected by the Editor of JAMA Health Forum as an Editor’s Choice: Clinical Trial of 2025.
Tatyana Avilova, PhD is an economist with expertise in applied microeconomics, focusing on healthcare and education.
Washington, DC
Tatyana Avilova is an economist with expertise in applied microeconomics, focusing on healthcare and education. Her research uses randomized controlled trials (RCTs), applied econometric methods, and surveys to analyze the impact of government and institutional policies on physicians, patients, students, and other individuals targeted by these policies. Dr. Avilova also has area expertise in the Japanese economy.
Prior to joining Secretariat, Dr. Avilova was an Assistant Professor at the Department of Economics at Bowdoin College and a Research Associate at the Institute of Social Science at the University of Tokyo. She has served as a referee at various journals, including the Journal of Health Economics, and as an editorial board member for the Social Science Japan Journal.
Dr. Avilova earned her Ph.D. in Economics from Columbia University. At Columbia, Dr. Avilova worked as a Teaching Fellow for eight course terms and received the Wueller Fellowship, awarded for excellence in teaching, for several years.
Before graduate school, she was the project manager for the Undergraduate Women in Economics Challenge, an initiative started by Nobel Laureate Dr. Claudia Goldin to encourage undergraduate women to major in economics. Dr. Avilova was also a 2013-14 Fulbright Fellow at the University of Tsukuba in Japan. She earned her B.A. in Economics (magna cum laude) from Harvard University.
She is fluent in English and Russian and has advanced proficiency in Japanese (N2 level on the Japanese Language Proficiency Test).
A recent study by Tatyana Avilova, Economist at Secretariat has been selected by the Editor of JAMA Health Forum as an Editor’s Choice: Clinical Trial of 2025.
Secretariat and Six Experts Earn Recognition in the 2026 IAM Patent 1000 Listing
Secretariat and six of the firm’s intellectual property experts have been recognized in the 2026 IAM Patent 1000 for their market-leading patent litigation expertise.
Making Patent Citations Count: Statistical Tools for Valuing Innovation in Litigation and Licensing
In Loyola Law Review, Richard Eichmann and Adam Rhoten examine how statistical normalization improves patent citation analysis in litigation and licensing. The article shows how normalized citation metrics provide a more rigorous framework for assessing technological significance and valuation.